This phase Ib/II trial studies the side effects of near-infrared image guided surgical resection with high-dose indocyanine green in treating patients with head and neck cancer. Near-infrared image guided surgical resection with indocyanine green may make it easier to find and remove tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03745690.
PRIMARY OBJECTIVE
I. To determine the safety profile of high-dose optical dye, indocyanine green, in head and neck cancer surgical patients.
SECONDARY OBJECTIVE:
I. Determine the efficacy of high-dose indocyanine green to identify cancer compared to surrounding normal tissue (tumor to background ratio; TBR) in head and neck cancer resections.
OUTLINE:
Patients receive indocyanine green intravenously (IV) on day 0 and undergo near-infrared image guided surgical resection over 2-4 hours on day 1.
After completion of study treatment, patients are followed up for 14-30 days.
Lead OrganizationUCLA / Jonsson Comprehensive Cancer Center
Principal InvestigatorAbie H. Avraham Mendelsohn